Platelet activation and aggregation signaling

Platelet activation and aggregation signaling is a multi-step biological process essential for hemostasis but also central to the pathogenesis of arterial thrombosis. The pathway is triggered by vascular injury, which exposes subendothelial matrix proteins like collagen and von Willebrand factor (vWF), leading to platelet adhesion via receptors such as GPVI and GPIb-IX-V (StatPearls, 2023, NBK545271). Upon adhesion, platelets undergo activation, characterized by shape change and the release of secondary mediators like adenosine diphosphate (ADP) and thromboxane A2 (TXA2), which amplify the recruitment of additional platelets (Nature Reviews Cardiology, 2017, PMID: 29143811). This signaling cascade culminates in the inside-out activation of the integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor, which binds fibrinogen to form stable platelet aggregates (Reactome, 2024, R-HSA-76002). Pharmacological intervention in this pathway, using agents like P2Y12 inhibitors or COX-1 inhibitors, is a cornerstone in preventing ischemic events in patients with cardiovascular disease (PubMed, 2019, PMID: 31101511). However, the primary therapeutic challenge remains balancing the prevention of pathological thrombosis with the maintenance of physiological hemostasis to avoid excessive bleeding.

Other names

Platelet activation pathwayPlatelet aggregation pathwayHemostasis signalingThrombocyte activation cascade

Inhibition of specific signaling nodes such as P2Y12 receptors, cyclooxygenase-1 (COX-1), or integrin alpha-IIb/beta-3 to prevent platelet activation and subsequent thrombus formation.